寶鼎科技(002552.SZ):招金集團取得公司控股權
格隆匯11月1日丨寶鼎科技(002552.SZ)公佈,2019年11月1日,公司接到招金集團通知,招金集團上報給招遠市國有資產監督管理局《關於招金集團收購寶鼎科技股份有限公司的請示》(招國資[2019]19號)已取得煙台市國資委出具的《關於山東招金集團有限公司收購寶鼎科技股份有限公司股份的批覆》(煙國資[2019]72號),同意招金集團通過協議受讓和部分要約收購方式收購寶鼎科技不少於約1.16億股股份,佔公司總股本比例不低於37.9%。收購完成後,招金集團將成為寶鼎科技第一大股東並取得控股權。
截止公告披露日,交易雙方簽訂的《股份轉讓協議》約定的生效條件已全部滿足,《股份轉讓協議》即日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.